FDA Diagnostics Office Seeks Bigger Role In Personalized Medicine
This article was originally published in The Gray Sheet
Executive Summary
FDA officials that regulate lab tests don't think they have been active enough in the policy debate over the future of personalized medicine; but, they say, that is about to change
You may also be interested in...
Regulatory Workaround, Not Statutory Changes, Better For Personalized Medicine Development, FDA Commissioner Hamburg Says
FDA Commissioner Margaret Hamburg said that working within the current regulatory framework rather than seeking new statutory authority to address the development of drugs and accompanying diagnostic tests would be preferable to address personalized medicine questions at the agency
FDA Plans Guidance This Year On Co-Development Of Diagnostics And Drugs
FDA expects to complete a guidance document on co-development of diagnostics and drugs used for personalized medicine by the end of this year, FDA Commissioner Margaret Hamburg said at a meeting in Washington, D.C., Feb. 25
FDA Plans Guidance This Year On Co-Development Of Diagnostics And Drugs
FDA expects to complete a guidance document on co-development of diagnostics and drugs used for personalized medicine by the end of this year, FDA Commissioner Margaret Hamburg said at a meeting in Washington, D.C., Feb. 25